Generic World Pharmacy

• Prostate cancer
• Endometriosis
• Uterine fibroids
• Precocious puberty (premature puberty)

Product Name: LDN - Low Dose Naltrexone Capsules (1.5mg/3mg/4.5mg)

Brand Name: LDN, Naltrexone-LD, Naltex-Low

Composition: Low Dose Naltrexone (1.5mg/3mg/4.5mg)

Manufacturer/Marketer: Healing Pharma India Private Limited

Packaging: To be provided (specify packaging details if available)

Treatment: Autoimmune disorders, chronic pain, inflammatory conditions

Product Description: LDN Capsules contain Low Dose Naltrexone, an opioid receptor antagonist with immunomodulatory effects. It is used in the management of autoimmune disorders, chronic pain conditions, and inflammatory diseases by modulating the immune system and reducing inflammation, helping to improve overall health and well-being

Xmalon 25mg Tablet is an aromatase inhibitor. It is used in the treatment of breast cancer in women who have gone through menopause. It works by adjusting the level of estrogen and helps in slowing down the growth of cancer cells.

Xmalon 25mg Tablet is also used in combination with medication in early cancer to prevent the risk of coming back. It should be taken with food, but take it at the same time every day to get the most benefit. It should be taken as your doctor's advice. The dose and how often you take it depends on what you are taking it for. Your doctor will decide how much you need to improve your symptoms. Swallow the tablets whole with a drink of water. You should take this medicine for as long as it is prescribed for you.

The most common side effects of the medicine include insomnia (difficulty sleeping), headache, nausea, increased appetite, and joint pain  If these bother you, or appear serious, let your doctor know. There may be ways of reducing or preventing them.

Before taking this medicine, tell your doctor if you are not gone through menopause and still having menstrual periods, or you have a problem with the liver or kidney. Your doctor should also know about all other medicines you are taking as many of these may make this medicine less effective or change the way it works. Tell your doctor if you are pregnant or breastfeeding. Your doctor may perform some blood tests to check for vitamin D level or bone density.

• Breast cancer

• Insomnia (difficulty in sleeping)
• Headache
• Nausea
• Increased sweating
• Musculoskeletal (bone, muscle or joint) pain
• Fatigue
• Increased appetite

Bosutris 100 Tablet is an anti-cancer medicine. It is used in the treatment of certain blood cancer known as chronic myeloid leukemia. This medicine helps to slow down the growth and multiplication of cancer cells, thereby reducing the progress of the disease.

Bosutris 100 Tablet should be taken as your doctor's advice. Your doctor will decide how much you need to take and for how long. You may take it with or without food. Take it regularly and take it at a fixed time each day to help you remember. You should not stop taking the medicine suddenly and continue taking it for as long as the doctor has prescribed.

Common side effects of this medicine include respiratory tract infection, nasopharyngitis, low blood platelets, decreased white blood cell count, anemia, headache, breathlessness, cough, increased liver enzymes,  diarrhea, vomiting, nausea, and abdominal pain. If any of these bothers you, let your doctor know. There may be ways of reducing or preventing them. You should also inform the doctor immediately if it causes severe headaches, swelling in one leg, pain on breathing, or changes in vision or hearing.

Before taking Bosutris 100 Tablet, you should let your doctor know if you have any other preexisting medical conditions. You should also inform the doctor about all other medicines that you are taking. Pregnant and breastfeeding women should not take this medicine as it can cause harmful effects to the developing baby.USES OF BOSUTRIS TABLET

• Blood cancer (Chronic myeloid leukaemia)

• Abdominal pain
• Nausea
• Vomiting
• Diarrhea
• Headache
• Cough
• Low blood platelets
• Anemia (low number of red blood cells)
• Nasopharyngitis (inflammation of the throat and nasal passages)
• Respiratory tract infection
• Decreased white blood cell count (neutrophils)
• Breathlessness
• Increased liver enzymes

Product Description:
Palnat 125 Capsule contains Palbociclib, a targeted cancer therapy known as a cyclin-dependent kinase (CDK) 4/6 inhibitor. It is used in combination with hormonal therapies to treat hormone receptor-positive, HER2-negative breast cancer. Palbociclib works by inhibiting the activity of CDK4 and CDK6, which are enzymes that promote cell division. By blocking these enzymes, Palbociclib slows the growth and spread of cancer cells.

Common indications for Palnat 125 Capsule include:

• Breast Cancer: Used in combination with an aromatase inhibitor as the first-line treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women. It is also used with fulvestrant in patients whose disease has progressed after endocrine therapy.

Dosage and Administration:

• For Adults: The recommended dose is 125 mg taken orally once daily for 21 consecutive days, followed by 7 days off treatment, making up a 28-day cycle.
• Administration: The capsule should be swallowed whole with water, preferably with food. It should not be chewed, crushed, or opened.

Common side effects of Palnat 125 Capsule may include:

• Neutropenia (low white blood cell count)
• Fatigue
• Nausea
• Diarrhea
• Infections
• Stomatitis (inflammation of the mouth)
• Thrombocytopenia (low platelet count)

Patients are advised to undergo regular blood tests to monitor blood cell counts during treatment, as well as to report any signs of infection or unusual symptoms to their healthcare provider immediately.

Packaging:
Palnat 125 Capsule is typically packaged in blister packs containing 21 capsules, which corresponds to one cycle of treatment.

Palnat 125 Capsule is an important medication in the treatment of advanced breast cancer, offering a targeted approach that, when used in combination with hormonal therapies, can help control the disease and improve survival outcomes. Adherence to the prescribed regimen and regular monitoring are essential to maximize the benefits of this therapy while managing potential side effects.

Product Description:
Opdyta 40mg Injection contains Nivolumab, an immune checkpoint inhibitor that targets the programmed death-1 (PD-1) pathway, a mechanism used by cancer cells to avoid being attacked by the immune system. By inhibiting PD-1, Nivolumab reactivates T-cells to recognize and destroy cancer cells. This immunotherapy is used to treat several types of advanced cancers, often in cases where other treatments have failed or are unsuitable.

Common indications for Opdyta 40mg Injection include:

• Melanoma: Used in the treatment of unresectable or metastatic melanoma.
• Non-Small Cell Lung Cancer (NSCLC): Approved for the treatment of metastatic NSCLC after platinum-based chemotherapy.
• Renal Cell Carcinoma (RCC): Used in the treatment of advanced RCC after prior anti-angiogenic therapy.
• Classical Hodgkin Lymphoma: For patients whose disease has relapsed or progressed after autologous hematopoietic stem cell transplantation and brentuximab vedotin.
• Head and Neck Cancer: Used in recurrent or metastatic squamous cell carcinoma of the head and neck.
• Urothelial Carcinoma: For patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy.
• Colorectal Cancer: Used for the treatment of metastatic colorectal cancer with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors.

Dosage and Administration:

• For Adults: The dosage varies based on the type of cancer being treated and the patient's body weight, typically administered as an intravenous infusion over 30 minutes every 2 or 4 weeks.
• Administration: Opdyta is administered as an intravenous infusion by a healthcare professional in a clinical setting. Dosage and frequency depend on the specific condition being treated and patient response.

Common side effects of Opdyta 40mg Injection may include:

• Fatigue
• Nausea
• Rash
• Diarrhea
• Anemia
• Hepatitis
• Colitis

Patients are closely monitored during treatment for potential immune-related adverse effects, which can affect various organs and require immediate medical attention.

Packaging:
Opdyta 40mg Injection is typically packaged in a single-use vial containing 4 mL of solution for infusion, designed for single-dose use.

Opdyta 40mg Injection represents a significant advancement in cancer immunotherapy, offering new treatment options for patients with various types of advanced cancers. By harnessing the body's immune system to fight cancer, Opdyta has become a vital component in the management of cancers that are otherwise difficult to treat. Close monitoring and adherence to the prescribed infusion schedule are crucial for maximizing the benefits of this therapy while managing potential side effects.

Product Description:
Tecentriq Atezolizumab Injection is an immune checkpoint inhibitor that targets the programmed death-ligand 1 (PD-L1) protein, helping the body’s immune system to detect and fight cancer cells. Atezolizumab works by blocking the interaction between PD-L1 and PD-1 receptors, which allows immune cells to attack and destroy cancer cells more effectively.

Common indications for Tecentriq Atezolizumab Injection include:

• Non-Small Cell Lung Cancer (NSCLC): Used as a first-line treatment in combination with chemotherapy for metastatic NSCLC.
• Urothelial Carcinoma: Indicated for patients with locally advanced or metastatic urothelial carcinoma who have progressed during or following platinum-containing chemotherapy.
• Triple-Negative Breast Cancer (TNBC): Used in combination with nab-paclitaxel for unresectable locally advanced or metastatic TNBC expressing PD-L1.

Dosage and Administration:

• For Adults: The typical dose is 1200 mg administered as an intravenous infusion every 3 weeks. The infusion is given over 60 minutes for the first dose and, if well-tolerated, over 30 minutes for subsequent doses.
• Administration: Tecentriq is administered as an intravenous infusion by a healthcare professional in a clinical setting. The dosage and frequency depend on the specific type of cancer being treated and the patient’s response to therapy.

Common side effects of Tecentriq Atezolizumab Injection may include:

• Fatigue
• Nausea
• Decreased appetite
• Cough
• Constipation
• Diarrhea
• Rash

Patients should be monitored for immune-mediated side effects, which can affect various organs and require prompt medical attention.

Packaging:
Tecentriq Atezolizumab Injection is typically packaged in a single-dose vial containing 20 mL of solution, designed for single-use only.

Tecentriq Atezolizumab Injection represents a significant advancement in cancer immunotherapy, offering new hope for patients with difficult-to-treat cancers. Its ability to harness the body’s immune system to fight cancer makes it a valuable option in the treatment of various advanced cancers. Close monitoring during treatment is essential to manage potential side effects and ensure the best possible outcomes for patients.

• Brand Name: Lenvenib 4mg Capsule
• Composition: Lenvatinib (4mg)
• Manufacturer/Marketer: Sun Pharmaceutical Industries Ltd
• Packaging: Strip of capsules
• Treatment:
  • Thyroid cancer (differentiated thyroid carcinoma resistant to radioactive iodine therapy)
  • Renal cell carcinoma (kidney cancer)
  • Hepatocellular carcinoma (liver cancer)

Lenvenib contains Lenvatinib, a tyrosine kinase inhibitor (TKI) that disrupts cancer growth by targeting specific proteins responsible for cell division and blood vessel formation in tumors. It is effective in advanced and metastatic cancers.

• Brand Name: Lenvatol 10mg Capsule
• Composition: Lenvatinib (10mg)
• Manufacturer/Marketer: Cipla Ltd
• Packaging: Strip of capsules
• Treatment: Used for the treatment of certain types of cancers, including:
  • Thyroid cancer
  • Kidney cancer (renal cell carcinoma)
  • Liver cancer (hepatocellular carcinoma)

Lenvatol contains Lenvatinib, a tyrosine kinase inhibitor (TKI) that blocks specific enzymes responsible for cancer cell growth and division. It also helps reduce tumor blood supply by inhibiting angiogenesis (formation of new blood vessels).

Product Name: Pazinib 400mg Tablet

Brand Name: Pazinib, Pazocip

Composition: Pazopanib (400mg)

Manufacturer/Marketer: Hetero Healthcare Limited

Packaging: To be provided (specify packaging details if available)

Treatment: Renal cell carcinoma (kidney cancer), advanced soft tissue sarcoma

Product Description: Pazinib 400mg Tablet contains Pazopanib, a tyrosine kinase inhibitor used in the treatment of advanced kidney cancer (renal cell carcinoma) and certain types of soft tissue sarcoma. It works by inhibiting the growth of cancer cells by blocking specific enzymes required for tumor growth and blood supply

Product Name: Axpero 5 Tablet

Brand Name: Axpero

Composition: Axitinib (5 mg)

Manufacturer/Marketer: Intas Pharmaceuticals Ltd

Packaging: Strip of tablets

Treatment: Advanced renal cell carcinoma (kidney cancer)

Product Description: Axpero 5 Tablet contains Axitinib, a tyrosine kinase inhibitor used in the treatment of advanced renal cell carcinoma (RCC). Axitinib works by blocking the growth of cancer cells and inhibiting the formation of blood vessels that supply tumors. This medication is prescribed for individuals with advanced-stage kidney cancer, particularly after the failure of other treatments. It requires a prescription and should be taken under the close supervision of an oncologist, with regular monitoring for side effects such as hypertension, diarrhea, or liver dysfunction.

Product Description:
Imbruvica 140mg Capsule contains Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor used in the treatment of several types of blood cancers. Ibrutinib works by blocking BTK, a protein that helps cancer cells survive and grow. By inhibiting this protein, Imbruvica interferes with the growth and spread of cancer cells, particularly in certain types of leukemia and lymphoma.

Common indications for Imbruvica 140mg Capsule include:

• Chronic Lymphocytic Leukemia (CLL): Used as a first-line treatment or in patients who have received at least one prior therapy.
• Small Lymphocytic Lymphoma (SLL): Treated similarly to CLL, targeting the same type of cancer cells.
• Mantle Cell Lymphoma (MCL): Used in patients who have received at least one prior therapy.
• Waldenström's Macroglobulinemia (WM): A rare type of non-Hodgkin lymphoma treated with Imbruvica.
• Marginal Zone Lymphoma (MZL): Used in patients who have received prior treatment with at least one anti-CD20-based therapy.

Dosage and Administration:

• For Adults: The dosage varies depending on the condition being treated but typically involves taking multiple 140 mg capsules to reach a total daily dose of 420 mg or 560 mg, depending on the specific disease.
• Administration: The capsule should be swallowed whole with water, taken once daily at the same time each day. It should not be opened, crushed, or chewed.

Common side effects of Imbruvica 140mg Capsule may include:

• Diarrhea
• Fatigue
• Nausea
• Musculoskeletal pain
• Bruising
• Rash

Imbruvica may also increase the risk of infections and bleeding, so patients should be monitored closely by their healthcare provider throughout the course of treatment.

Packaging:
Imbruvica 140mg Capsule is typically packaged in bottles containing 90 or 120 capsules, designed to last for one or more months of treatment depending on the prescribed dosage.

Imbruvica 140mg Capsule is a critical component in the treatment of certain blood cancers, offering a targeted approach that has significantly improved outcomes for many patients with these conditions. Adherence to the prescribed regimen and close monitoring are crucial to managing the treatment effectively and mitigating potential side effects.

Product Description:
Tagrisso 80mg Tablet contains Osimertinib, a targeted cancer therapy used in the treatment of non-small cell lung cancer (NSCLC) that has specific mutations in the epidermal growth factor receptor (EGFR). Osimertinib is an EGFR tyrosine kinase inhibitor (TKI) that works by blocking the activity of the mutated EGFR, which drives the growth and spread of cancer cells. It is particularly effective against NSCLC that has developed resistance to other EGFR inhibitors.

Common indications for Tagrisso 80mg Tablet include:

• Cancer Treatment: Used in the management of non-small cell lung cancer (NSCLC) with specific EGFR mutations.

Dosage and Administration:

• For Adults: The typical dose is one 80 mg tablet taken orally once daily. The exact dosage and duration of treatment are determined by the oncologist based on the patient's condition and response to therapy.
• Administration: Tagrisso should be taken with or without food, and at the same time each day.

Common side effects of Tagrisso 80mg Tablet may include:

• Diarrhea
• Rash
• Dry skin
• Stomatitis (inflammation of the mouth)
• Nail changes

Serious side effects can include interstitial lung disease, QT prolongation (a type of heart rhythm problem), and low blood cell counts. Regular monitoring of lung function, heart function, and blood tests is essential during treatment.

Packaging:
Tagrisso 80mg Tablet is typically packaged in a box containing 30 tablets, with each tablet individually sealed to ensure proper dosage and patient safety.

Tagrisso 80mg Tablet is a vital medication in the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. It offers a targeted approach that can significantly improve outcomes for patients with this type of cancer. However, due to its potential for serious side effects, it should be used under the guidance and supervision of an experienced oncologist. Regular monitoring of patient health and response to therapy is crucial during treatment with Osimertinib.

Product Description:
Anaridex (Anastrozole) is a potent aromatase inhibitor used to treat hormone receptor-positive breast cancer in postmenopausal women. By lowering estrogen levels, Anastrozole helps slow down or stop the growth of cancer cells that rely on estrogen to grow.

Indications:

• Hormone receptor-positive breast cancer in postmenopausal women
• Adjuvant treatment of early breast cancer
• Treatment of advanced breast cancer

Dosage and Administration:
Typically, Anaridex is taken once daily, with or without food, as prescribed by a healthcare provider. The standard dose is 1 mg per day.

Common side effects include:

• Hot flashes
• Fatigue
• Joint pain
• Osteoporosis

Packaging:
Anaridex is available in blister packs containing 10 tablets each.

• Note:
• Mab Thera is a prescription drug and should be used under proper medical guidance and advice. Do not share the medicine with others, since they may be suffering from a problem that is not effectively treated by this drug.

• Aromasin is used to treat breast cancer in postmenopausal women
• It is often given to women whose cancer has progressed even after surgery, radiation, or other cancer medications have been tried without success

Product Description:
Bracanat 150mg Tablet contains Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor used in the treatment of various cancers, particularly those associated with BRCA gene mutations. Olaparib works by blocking the PARP enzyme, which helps repair damaged DNA in cells. By inhibiting this enzyme, Olaparib prevents cancer cells from repairing themselves, leading to their death.

Common indications for Bracanat 150mg Tablet include:

• Ovarian Cancer: Used in the maintenance treatment of adult patients with advanced ovarian cancer who have responded to first-line platinum-based chemotherapy.
• Breast Cancer: Used in the treatment of HER2-negative breast cancer with BRCA1/2 mutations.
• Pancreatic Cancer: Used in the maintenance treatment of BRCA-mutated metastatic pancreatic cancer.
• Prostate Cancer: Used in the treatment of metastatic castration-resistant prostate cancer with BRCA1/2 mutations.

Dosage and Administration:

• For Adults: The usual recommended dose is 300 mg (two 150 mg tablets) taken orally twice daily, for a total daily dose of 600 mg.
• Administration: The tablet should be swallowed whole with water, taken at approximately the same times each day, with or without food. It should not be crushed, chewed, or split.

Common side effects of Bracanat 150mg Tablet may include:

• Nausea
• Fatigue
• Anemia
• Vomiting
• Diarrhea
• Loss of appetite

Regular blood tests and monitoring are essential during treatment to manage potential side effects and adjust the dosage as needed.

Packaging:
Bracanat 150mg Tablet is typically packaged in blister packs containing 14 tablets, designed for a one-week course of treatment when taken as prescribed.

Bracanat 150mg Tablet is a significant advancement in cancer treatment, offering targeted therapy for patients with specific genetic mutations. It plays a crucial role in extending survival and improving the quality of life for patients with certain types of advanced cancers, particularly those associated with BRCA mutations. Regular monitoring and adherence to the prescribed regimen are vital to achieving the best possible outcomes.